Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Biophys Res Commun. 2003 Jan 10;300(2):285-90.

Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin.

Author information

  • 1Division of Urology, Urological Research Laboratory, Beth Israel Deaconess Medical Center, Dana 838, 330 Brookline Ave., Boston, MA 02115, USA. wschoppe@caregroup.harvard.edu

Abstract

We previously characterized a peanut agglutinin-binding tumor antigen, gp200, a surface membrane glycoprotein expressed on human embryonal carcinoma, a malignant stem cell of testicular tumors. Gp200 is remarkably similar to another embryonal carcinoma antigen, GCTM-2, a cell differentiation marker that is also detected in blood of testis cancer patients, yet neither molecular identity is known. We now report the identity of gp200 as podocalyxin. Protein sequence results of gp200 peptides match with podocalyxin sequence. Furthermore, two distinct monoclonal antibodies, specific for podocalyxin, react positively with gp200. Therefore, gp200 is a testicular tumor form of podocalyxin, a surface membrane glycoprotein that was originally discovered as a scaffolding extracellular matrix protein of kidney podocyte cells. Podocalyxin is also expressed on subsets of hematopoietic cells where it has a putative function as a cell adhesion protein. This is the first report of podocalyxin expression on malignant cells.

PMID:
12504081
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center